Coeptis Therapeutics Holdings, Inc.
COEP
$9.48
$0.010.11%
| Weiss Ratings | COEP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | COEP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | COEP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.60 | |||
| Price History | COEP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.74% | |||
| 30-Day Total Return | -28.18% | |||
| 60-Day Total Return | 65.73% | |||
| 90-Day Total Return | 143.45% | |||
| Year to Date Total Return | 60.41% | |||
| 1-Year Total Return | 50.62% | |||
| 2-Year Total Return | -67.98% | |||
| 3-Year Total Return | -95.30% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -30.88% | |||
| 52-Week Low % Change | 309.96% | |||
| Price | COEP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $13.70 | |||
| 52-Week Low Price | $2.31 | |||
| 52-Week Low Price (Date) | Dec 31, 2024 | |||
| 52-Week High Price (Date) | Jan 30, 2025 | |||
| Valuation | COEP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 26.97M | |||
| Enterprise Value | 27.77M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -6.44 | |||
| Earnings Per Share Growth | -65.89% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 3.92 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $9.48 | |||
| Enterprise Value/EBITDA (TTM) | -2.71 | |||
| Enterprise Value/EBIT | -2.47 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | COEP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.99M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | COEP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 724 934 6467 | |||
| Address | 105 Bradford Road Wexford, PA 15090 | |||
| Website | coeptistx.com | |||
| Country | United States | |||
| Year Founded | 2017 | |||
| Profitability | COEP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | COEP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -103.27% | |||
| Return on Equity | -- | |||
| Income Statement | COEP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -10.26M | |||
| EBIT (TTM) | -11.26M | |||
| Net Income (TTM) | -11.62M | |||
| Net Income Avl. to Common (TTM) | -11.62M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 71.20% | |||
| EPS Diluted (TTM) | -6.44 | |||
| EPS Diluted Growth (Q YOY) | 80.74% | |||
| Balance Sheet | COEP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.14M | |||
| Cash Per Share (Q) | $0.57 | |||
| Total Current Assets (Q) | 1.36M | |||
| Total Preferred Equity (Q) | 0.00 | |||
| Total Equity (Q) | 4.98M | |||
| Current Ratio (Q) | 0.397 | |||
| Book Value Per Share (Q) | $2.41 | |||
| Total Assets (Q) | 8.96M | |||
| Total Current Liabilities (Q) | 3.44M | |||
| Total Debt (Q) | 1.78M | |||
| Total Liabilities (Q) | 3.97M | |||
| Total Common Equity (Q) | 4.82M | |||
| Cash Flow | COEP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -100.00K | |||
| Cash from Financing (TTM) | 6.73M | |||
| Net Change in Cash (TTM) | -274.10K | |||
| Levered Free Cash Flow (TTM) | -3.17M | |||
| Cash from Operations (TTM) | -6.91M | |||
